06 June 2019
Visiongain has launched a new pharma report Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy.
Over the past ten years, there has been a paradigm shift in the treatment of cancer, driven by advances in personalised medicine and immuno-oncology. The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.
The lead analyst of the report commented "The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously. Thus, Visiongain believes that the focus on oncology and precision oncology diagnostics will remain high over the next decade driven by the ongoing research and development and growing number of partnerships between pharmaceutical and diagnostics players in this field.
Novel trends such as development of liquid biopsy-based tests will revolutionise the future of precision cancer diagnostic tests and as a result of this; the market will continue to achieve strong revenue growth."
Leading companies featured in the report include Abbott Laboratories, Agilent Technologies, Inc., bioMerieux SA, Genomic Health, Inc., Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Holding AG, Siemens Healthineers, Thermo Fisher Scientific, Inc. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.
27 May 2020
The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.
27 May 2020
The automation in biopharma industry market is estimated to grow at a CAGR of 4.3% over the forecast period.
22 May 2020
The global erectile dysfunction is in a transition phase as the majority of the consumers are shifting from traditional pharmaceuticals to herbal-based products pertaining to lesser side effects and positive perception of natural products amongst the society. Visiongain understands this market to be dynamic, with a large number of players to enter the market.”